Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LILIANA MONTOYA

NPI
1245255793
CMS profile
55893
Location
PORT CHARLOTTE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,687.54

84 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,549.55 82
Education $137.99 2

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LILIANA MONTOYA

NPI 1245255793 · CMS profile ID 55893

PORT CHARLOTTE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1245255793?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LILIANA MONTOYA, NPI 1245255793, CMS profile ID 55893. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245255793?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). LILIANA MONTOYA, NPI 1245255793, CMS profile ID 55893. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245255793?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
LILIANA MONTOYA, NPI 1245255793, CMS profile ID 55893, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1245255793?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

84 matching records · $1,687.54 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 84 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–84 of 84.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
NOVARTIS PHARMACEUTICALS CORPORATION $15.1206/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815001789 CMS
Alexion Pharmaceuticals, Inc. $21.7405/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783117311 CMS
Neurocrine Biosciences, Inc. $21.7005/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837806393 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $10.5305/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815001795 CMS
Adamas Pharmaceuticals, Inc. $19.4805/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834401985 CMS
EMD Serono, Inc. $16.5005/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849189587 CMS
GE HEALTHCARE $13.3405/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837885519 CMS
Kyowa Kirin, Inc. $11.2504/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852989481 CMS
Amgen Inc. $12.3104/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825555703 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $15.9604/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815001783 CMS
Allergan, Inc. $12.0804/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792879379 CMS
Lilly USA, LLC $12.4404/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937114093 CMS
Amneal Pharmaceuticals LLC $24.0803/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829669913 CMS
Biogen, Inc. $10.9403/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827844713 CMS
AbbVie Inc. $23.7403/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795748187 CMS
E.R. Squibb & Sons, L.L.C. $19.4403/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783423219 CMS
Neurocrine Biosciences, Inc. $24.6603/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837806391 CMS
Biogen, Inc. $24.4203/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827844725 CMS
Biohaven Pharmaceuticals, Inc. $27.2903/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852570053 CMS
EMD Serono, Inc. $17.8803/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849169921 CMS
UCB, Inc. $13.0303/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807318427 CMS
Biogen, Inc. $16.1702/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827844719 CMS
Adamas Pharmaceuticals, Inc. $22.5002/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834401983 CMS
EMD Serono, Inc. $12.8302/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849160293 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $13.7902/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815001775 CMS
Amgen Inc. $15.4102/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825555699 CMS
Allergan, Inc. $12.6002/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792879377 CMS
Eisai Inc. $21.6402/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845772541 CMS
Teva Pharmaceuticals USA, Inc. $14.0302/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839453055 CMS
UCB, Inc. $30.5701/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807307255 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $14.1901/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815001769 CMS
Biogen, Inc. $24.4201/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827844717 CMS
AbbVie Inc. $22.1501/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795748181 CMS
Neurocrine Biosciences, Inc. $25.8201/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837806389 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,217.15 61
PY2020 $1,303.74 68
PY2021 $1,687.54 84
PY2022 $3,730.86 64
PY2023 $1,553.76 66
PY2024 $1,119.10 49
PY2025 $1,729.93 59

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $187,296.11 67
PY2024 Principal investigator $618,392.71 83
PY2023 Principal investigator $636,869.55 31
PY2022 Principal investigator $482,270.75 19
PY2021 Principal investigator $418,370.42 39
PY2020 Principal investigator $479,493.89 63
PY2019 Principal investigator $569,424.61 153

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

67 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.34 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.00 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $180.06 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.71 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $180.06 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.34 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.34 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.00 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.00 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.71 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56.94 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.34 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.42 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.42 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.71 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.42 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.34 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.00 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.34 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.34 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.34 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56.94 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $180.06 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.71 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $180.06 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.71 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56.94 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.34 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.71 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.71 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.71 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.00 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.00 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56.94 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.71 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $180.06 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.71 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.42 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.71 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.71 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.34 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56.94 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.34 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.34 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56.94 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.42 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.42 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.71 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $180.06 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.42 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.71 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $268.00 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.34 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $180.06 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.34 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56.94 10/29/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254595
Principal investigator 1 Novartis Pharmaceuticals Corporation $64,884.57 10/21/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190302863
Principal investigator 1 Roche Products Limited $244.00 09/24/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628553
Principal investigator 1 Roche Products Limited $244.00 09/24/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628557
Principal investigator 1 Roche Products Limited $244.00 09/24/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628560
Principal investigator 1 Roche Products Limited $122.00 09/24/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628563
Principal investigator 1 Celgene Corporation $1,100.00 08/15/2025 Non-covered Recipient Entity
Neurology, Pa
A PHASE 3B, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOLOGICAL RESPONSE TO, AND THE SAFETY OF, THREE PARENTERALLY ADMINISTERED VACCINES IN SUBJECTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO RECEIVE ORAL OZANIMOD, NON-PEGYLATED INTERFERON-, OR NO DISEASE MODIFYING THERAPY No dispute reported 06/30/2026 1222307107
Principal investigator 1 Roche Products Limited $244.00 06/25/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628549
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $4,159.08 03/08/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
A PHASE 3, MULTICENTER, LONG-TERM, EXTENSION STUDY OF THE SAFETY AND EFFICACY OF AVP-786 (DEUTERATED [D6] DEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1225335651
Principal investigator 1 Novartis Pharmaceuticals Corporation $103,259.21 02/28/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190306463
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,280.96 01/30/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190306459
Principal investigator 1 Novartis Pharmaceuticals Corporation $256.65 01/01/2025 Non-covered Recipient Entity
NEUROSTUDIES INC
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190306461